2025-02-14 IDOPRESS
SEOUL,South Korea,Feb. 13,2025 -- DAAN Biotherapeutics,a leading innovative drug development company specializing in T-cell receptor (TCR)- based therapies,has signed an exclusive licensing agreement with LigaChem Biosciences for a novel tumor-targeting antibody to advance the development and commercialization of Antibody-Drug Conjugates (ADC).
By leveraging DAAN Biotherapeutics' next-generation antibody technology,built upon its exceptional target discovery and antibody development capabilities,LigaChem Biosciences is now positioned to take a significant step forward in ADC development for solid tumor patients.
DAAN Biotherapeutics has successfully established a proprietary pipeline for efficiently developing antibodies targeting overexpressed tumor targets in solid cancers through a strategic partnership with OmniAb.
Byoung Chul Cho,MD,the CEO of DAAN Biotherapeutics,stated,"We will continue to develop state-of-the-art antibodies targeting solid tumors and collaborate with global pharmaceutical companies in the ADC field. Beyond ADCs,we also aim to become a global leader in solid tumor-targeting T-cell engagers using our proprietary TACTIC (Tumor Targeting Conditionally Activated T Cell Engager) platform."
Global Launch of World Cultural Cities·Celebrity Interviews as a Prelude to the 2025 Beijing Cultural Forum
Hainan Discovery 2025 – Global Travel Delegates Program Concludes Successfully,Showcasing the Island’s Romantic Charms
us officials 'have stopped ukraine firing missiles at russia for months'
'vibrant' woman dies after rare allergic reaction during common scan
israel carries out dozens of strikes on yemen's capital near presidential palace
mystery billionaire behind \u00a310,000,000 plans for first titanic trip since titan disaster
©copyright2009-2020Fresh life